Enterprise-grade development pipelines: from high-throughput phytochemical identification to commercial-scale extraction and regulatory Phase I–IV validation.
Transitioning from unstandardized crude botanical powders to purified, pharmacologically characterized phytochemical actives for global pharmaceuticals, dietary supplements, and cosmeceuticals.
Global end-users are moving away from broad holistic claims toward clinically backed efficacy. Buyers in North America and Western Europe demand third-party verified mechanisms of action (MoA), requiring brands to source herbal actives containing documented percentages of target flavonoids, polyphenols, terpenoids, or alkaloids.
Authorities like the US FDA (NDI/GRAS), European EFSA, and China's NMPA have instituted rigorous chromatographic fingerprinting, genotoxicity documentation, and contaminant thresholds. Pure herbal extraction without verified chemical profiles risks multi-million-dollar import rejections and product recalls.
Brand owners no longer invest in in-house agronomy, extraction towers, or toxicological testing facilities. They leverage specialized Contract Development and Manufacturing Organizations (CDMOs) like MedGence (Yineng Pharma) capable of managing the lifecycle from phytochemistry discovery to commercial finished dosage.
Herbal actives cannot be deployed via a one-size-fits-all model. We engineer tailored molecular fractions aligned with specific consumer habits, taste profiles, delivery mechanisms, and legal classifications in key global territories.
Target Formats: Functional gummies, nootropic RTD beverages, and clean-label dietary capsules. Our actives are optimized for debittering, rapid gastric release, and instant water solubility for beverage bottling.
Target Formats: Traditional Herbal Medicinal Products (THMPD) and pharmaceutical phytotherapeutics. Requires strict quantification of declared active markers alongside polycyclic aromatic hydrocarbons (PAH) screening.
Target Formats: High-concentration oral liquids, anti-aging collagen shots, and hospital preparations. Formulations leverage modernized classic TCM combinations that align with local cultural trust.
Target Formats: Dermocosmetic serums, microemulsions, barrier creams, and scalp health treatments. Botanical extracts are refined to be scent-neutral, color-stable, non-comedogenic, and non-irritating.
Operating from Changsha, Hunan—the nexus of raw TCM cultivation and cutting-edge pharmaceutical bioprocessing—our integrated supply ecosystem ensures unrivaled cost advantage, security of supply, and rapid commercialization.
China commands over 80% of the world's commercial botanical feedstock diversity. We maintain long-term Good Agricultural Practice (GAP) sourcing partnerships across key geographical macro-climates (Hunan, Yunnan, Sichuan, Anhui), securing first-harvest selection privileges at cost bases unattainable by Western extraction plants.
Our facilities deploy low-temperature supercritical CO2, ultrasonic cavitation, and continuous dynamic countercurrent extraction lines. This architecture minimizes solvent degradation of thermolabile bioactives, boosts active recovery by 35%, and cuts energy consumption by 40% compared to traditional batch kettles.
Unlike broker-traders who outsource extraction to untracked sub-factories, MedGence directly governs the research-to-plant lifecycle. Our 300+ scientists oversee the entire transfer from analytical proof-of-concept to pilot 100L runs, straight into GMP commercial scale-up of liquids, softgels, capsules, or granules.
A verifiable operational track record developed in close collaboration with China's tier-1 pharmaceutical corporations, research universities, and clinical TCM hospitals.
Where biology meets computational chemistry: integrating artificial intelligence and biotransformation to engineer the next generation of highly targeted natural therapeutics.
Deploying in silico virtual screening against target biological receptors (e.g., AMPK, GLP-1R, COX-2) to identify high-affinity secondary metabolites from our proprietary library of over 100,000 herbal batches before wet-lab synthesis.
Employing specialized microbial biocatalysis to cleave sugar moieties on botanical glycosides, converting inactive precursors into highly bioavailable aglycones (e.g., transforming Ginsenoside Rb1 to rare ginsenoside Compound K).
Formulating insoluble polyphenols and curcumins inside phospholipid bilayers and lipid nanoparticles (LNPs), multiplying active cell-membrane permeability by up to 800% while shielding actives from stomach acid degradation.
Implementing inline NIR (Near-Infrared) sensors and automated feedback control systems across our pilot plants, guaranteeing instant detection and compensation for variations in botanical biomass moisture and yield.
Navigating global border clearances, import certifications, and therapeutic health registrations with structured technical dossiers prepared by certified international regulatory affairs experts.
Every commercial supply delivery is accompanied by full Certificate of Analysis (CoA) documentation verified by HPTLC identification, HPLC quantitative analysis, and GC residual solvent testing conforming to USP/EP pharmacopeial thresholds.
We provide complete preclinical toxicology packages required for novel registrations: acute LD50 toxicology, sub-chronic toxicity assays, Ames mutagenicity testing, and in vivo erythrocyte micronucleus tests executed under strict GLP adherence.
Our regulatory logistics team assists global buyers with phytosanitary certificates, non-endangered species CITES clearance, irradiation-free declarations, allergen checklists, and customs HS code optimization to prevent port demurrage delays.
Our scientific credibility is demonstrated by our ongoing contract manufacturing and development agreements with China's most esteemed medical and pharmaceutical leaders.
Detailed guidance for procurement heads, formulation scientists, and brand directors evaluating botanical CDMO contracts.
MedGence (Yineng Pharma) provides an end-to-end continuum rarely found under one roof: from botanical raw-material screening and seasonal potency mapping to chromatographic method development, in vitro assays, GLP animal models, Phase I–IV human clinical trials, and final industrial cGMP manufacturing across both active ingredients and finished dose formats.
Yes. Our in-house research labs and industrial pilot plants are governed directly by our 300+ technical personnel. This completely eliminates the costly tech-transfer friction, intellectual property leakages, and formulation redesigns that typically happen when separating research CROs from bulk CDMO production plants.
Depending on target bioactives, our analytical suites use High-Performance Thin-Layer Chromatography (HPTLC) for fingerprint identity, High-Performance Liquid Chromatography (HPLC-DAD/ELSD), Gas Chromatography-Mass Spectrometry (GC-MS), and ICP-MS for heavy metal quantification. Every batch must meet defined chemical similarity benchmarks against official reference standards.
We work exclusively under bilateral non-disclosure and entrusted contract manufacturing charters. Your extraction parameters, unique molecular fractions, and custom formula ratios are isolated under encrypted project access codes, guaranteeing that your brand retains absolute exclusivity and market advantage.
Active pharmaceutical ingredients can be delivered as ultra-concentrated standardized liquids, spray-dried micro-powders, pasty extracts, and pure volatile essential oils. For finished formulations, our cGMP partner lines produce oral liquids, hard-shell capsules, softgels, bi-layer tablets, effervescent granules, and instant-dissolve soluble sachets.
Yes. We organize controlled human pilot trials for dietary claims substantiation as well as full GCP-compliant Phase I, II, III, and IV clinical trials in conjunction with Chinese university hospitals and clinical medical centers to provide data packages required for novel therapeutic approvals.
Direct supply contracts, analytical method validation packages, and contract research deliverables available for global contract booking.
Collaborate directly with our Changsha scientific headquarters to scope custom botanical screening, analytical method development, or industrial CDMO manufacturing.